240 related articles for article (PubMed ID: 9445190)
1. A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix.
Irvin WP; Price FV; Bailey H; Gelder M; Rosenbluth R; Durivage HJ; Potkul RK
Cancer; 1998 Jan; 82(2):328-33. PubMed ID: 9445190
[TBL] [Abstract][Full Text] [Related]
2. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
Rothenberg ML; Cox JV; DeVore RF; Hainsworth JD; Pazdur R; Rivkin SE; Macdonald JS; Geyer CE; Sandbach J; Wolf DL; Mohrland JS; Elfring GL; Miller LL; Von Hoff DD
Cancer; 1999 Feb; 85(4):786-95. PubMed ID: 10091755
[TBL] [Abstract][Full Text] [Related]
3. A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.
Kakolyris S; Souglakos J; Agelaki S; Kourousis CH; Mavroudis D; Sarra E; Malliotakis P; Georgoulias V
Lung Cancer; 2000 Dec; 30(3):193-8. PubMed ID: 11137204
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: a gynecologic oncology group study.
Look KY; Blessing JA; Levenback C; Kohler M; Chafe W; Roman LD
Gynecol Oncol; 1998 Sep; 70(3):334-8. PubMed ID: 9790784
[TBL] [Abstract][Full Text] [Related]
6. A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma.
Mühr-Wilkenshoff F; Hinkelbein W; Ohnesorge I; Wolf KJ; Riecken EO; Zeitz M; Scherübl H
Int J Colorectal Dis; 2003 Jul; 18(4):330-4. PubMed ID: 12774248
[TBL] [Abstract][Full Text] [Related]
7. Low-dose irinotecan as a second-line chemotherapy for recurrent small cell lung cancer.
Morise M; Niho S; Umemura S; Matsumoto S; Yoh K; Goto K; Ohmatsu H; Ohe Y
Jpn J Clin Oncol; 2014 Sep; 44(9):846-51. PubMed ID: 25057092
[TBL] [Abstract][Full Text] [Related]
8. Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix.
Lhommé C; Fumoleau P; Fargeot P; Krakowski Y; Dieras V; Chauvergne J; Vennin P; Rebattu P; Roche H; Misset JL; Lentz MA; Van Glabbeke M; Matthieu-Boué A; Mignard D; Chevallier B
J Clin Oncol; 1999 Oct; 17(10):3136-42. PubMed ID: 10506610
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.
Fukuoka M; Niitani H; Suzuki A; Motomiya M; Hasegawa K; Nishiwaki Y; Kuriyama T; Ariyoshi Y; Negoro S; Masuda N
J Clin Oncol; 1992 Jan; 10(1):16-20. PubMed ID: 1309380
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma.
Poon D; Chowbay B; Cheung YB; Leong SS; Tan EH
Cancer; 2005 Feb; 103(3):576-81. PubMed ID: 15612023
[TBL] [Abstract][Full Text] [Related]
11. Salvage chemotherapy with CPT-11 for recurrent meningioma.
Chamberlain MC; Tsao-Wei DD; Groshen S
J Neurooncol; 2006 Jul; 78(3):271-6. PubMed ID: 16628476
[TBL] [Abstract][Full Text] [Related]
12. [An early phase II study of CPT-11 (irinotecan hydrochloride) in patients with advanced breast cancer].
Taguchi T; Yoshida Y; Izuo M; Ishida T; Ogawa M; Nakao I; Tominaga T; Ohkawa T; Oguro M; Yoshida M
Gan To Kagaku Ryoho; 1994 Jan; 21(1):83-90. PubMed ID: 8291919
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
Rougier P; Bugat R; Douillard JY; Culine S; Suc E; Brunet P; Becouarn Y; Ychou M; Marty M; Extra JM; Bonneterre J; Adenis A; Seitz JF; Ganem G; Namer M; Conroy T; Negrier S; Merrouche Y; Burki F; Mousseau M; Herait P; Mahjoubi M
J Clin Oncol; 1997 Jan; 15(1):251-60. PubMed ID: 8996150
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix.
Verschraegen CF; Levy T; Kudelka AP; Llerena E; Ende K; Freedman RS; Edwards CL; Hord M; Steger M; Kaplan AL; Kieback D; Fishman A; Kavanagh JJ
J Clin Oncol; 1997 Feb; 15(2):625-31. PubMed ID: 9053486
[TBL] [Abstract][Full Text] [Related]
15. [A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 Cooperative Study Group].
Negoro S; Fukuoka M; Niitani H; Suzuki A; Nakabayashi T; Kimura M; Motomiya M; Kurita Y; Hasegawa K; Kuriyama T
Gan To Kagaku Ryoho; 1991 May; 18(6):1013-9. PubMed ID: 1851408
[TBL] [Abstract][Full Text] [Related]
16. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.
Pitot HC; Goldberg RM; Reid JM; Sloan JA; Skaff PA; Erlichman C; Rubin J; Burch PA; Adjei AA; Alberts SA; Schaaf LJ; Elfring G; Miller LL
Clin Cancer Res; 2000 Jun; 6(6):2236-44. PubMed ID: 10873073
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.
Catimel G; Chabot GG; Guastalla JP; Dumortier A; Cote C; Engel C; Gouyette A; Mathieu-Boué A; Mahjoubi M; Clavel M
Ann Oncol; 1995 Feb; 6(2):133-40. PubMed ID: 7786821
[TBL] [Abstract][Full Text] [Related]
18. [A late phase II study of CPT-11, irinotecan hydrochloride, in patients with advanced pancreatic cancer. CPT-11 Study Group on Gastrointestinal Cancer].
Sakata Y; Shimada Y; Yoshino M; Kambe M; Futatsuki K; Nakao I; Ogawa N; Wakui A; Taguchi T
Gan To Kagaku Ryoho; 1994 Jun; 21(7):1039-46. PubMed ID: 8210255
[TBL] [Abstract][Full Text] [Related]
19. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study.
Jagasia MH; Langer CJ; Johnson DH; Yunus F; Rodgers JS; Schlabach LL; Cohen AG; Shyr Y; Carbone DP; Devore RF
Clin Cancer Res; 2001 Jan; 7(1):68-73. PubMed ID: 11205920
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of irinotecan in patients with advanced hepatocellular carcinoma.
O'Reilly EM; Stuart KE; Sanz-Altamira PM; Schwartz GK; Steger CM; Raeburn L; Kemeny NE; Kelsen DP; Saltz LB
Cancer; 2001 Jan; 91(1):101-5. PubMed ID: 11148565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
